Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
lapemelanotide zapixetar
product6 mentionslast seen Nov 9, 2026
A clinical-stage program in development for melanoma.
Relationships 6
- Perspective Therapeutics, Inc.developslapemelanotide zapixetar99% confidence6 sources
- lapemelanotide zapixetarapplies tomelanoma99% confidence3 sources
- lapemelanotide zapixetarapplies tomelanoma treatment99% confidence2 sources
- lapemelanotide zapixetarapplies tometastatic melanoma treatment92% confidence1 source
- lapemelanotide zapixetarcomposed of212Pb92% confidence1 source
- lapemelanotide zapixetardepends onlead-21292% confidence1 source
Relationship
lapemelanotide zapixetarapplies tomelanoma
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGARNov 6, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
lapemelanotide zapixetar (VMT01, melanoma)
- filingSEC EDGAROct 1, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma
- filingSEC EDGARSep 14, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
lapemelanotide zapixetar (VMT01, melanoma)